15.66
0.90%
0.14
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
How To Trade (INBX) - Stock Traders Daily
why ImmunityBio Inc [IBRX] is a Good Choice for Investors After New Price Target of $6.38 - The DBT News
INVX underperforms with a -2.86 decrease in share price - US Post News
You might want to take a look at Imunon Inc (IMNN) now - SETE News
Immuneering Corp [IMRX] Shares Fall Approximately -71.25% Over the Year - Knox Daily
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Private Advisor Group LLC - Defense World
Incyte (NASDAQ:INCY) Given “Hold” Rating at Truist Financial - Defense World
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Down 6.9% in August - Defense World
InnovAge (NASDAQ:INNV) Trading Up 4.2% - Defense World
William Hoffman Sells 40,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest - Defense World
INmune Bio stock remains a Buy with positive data correlation in Alzheimer’s study, says Scotiabank - Investing.com
A review of IMNN’s current quarter earnings predictions - US Post News
Its Stock Has Paid Off Big Time For INmune Bio Inc - SETE News
Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update - MarketBeat
IBRX Stock on the Rise: A Promising Investment - The InvestChronicle
Market Watch: Immuneering Corp (IMRX)’s Noteworthy Drop, Closing at 2.78 - The Dwinnex
Truist downgrades Incyte to "hold" on doubts of near-term prospects - XM
Incyte (NASDAQ:INCY) Receives Market Perform Rating from JMP Securities - Defense World
Imunon (NASDAQ:IMNN) Shares Up 5.6% - Defense World
Ratio Review: Analyzing Innovex International Inc. (INVX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
10% Owner Of Impinj Makes $20.00M Buy - Benzinga
Inmune Bio CFO acquires $49k in company stock By Investing.com - Investing.com Canada
Inmune Bio CEO acquires $98k in company stock - Investing.com
Inmune Bio CFO buys $49k in company stock - Investing.com
Inhibrx CEO buys shares worth over $629k - Investing.com India
Inhibrx CEO buys shares worth over $629k By Investing.com - Investing.com Canada
Inhibrx CEO buys shares worth over $629k - Investing.com
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Inhibrx CEO buys shares worth over $629k By Investing.com - Investing.com UK
How will ImmunityBio Inc’s (IBRX) earnings compare to estimates this quarter? - US Post News
What is IMRX’s price-to-sales ratio telling us about the company’s value? - US Post News
Impinj 10% Owner Trades $20.00M In Company Stock - Benzinga
Take off with ImmunityBio Inc (IBRX): Get ready for trading - SETE News
SEC Form 424B5 filed by INmune Bio Inc. - Quantisnow
Financial Metrics Check: ImmunityBio Inc (IBRX)’s Ratios for Trailing Twelve Months - The Dwinnex
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study - Yahoo Finance
What is Immuneering Corp (IMRX) Stock Return on Shareholders’ Capital? - SETE News
IMRX stock rated a Buy by Needham - Knox Daily
Immuneering’s (IMRX) Buy Rating Reiterated at Needham & Company LLC - Defense World
Inhibrx: The Biotech Spinoff Poised For Big Gains - Forbes
(INBX) Long Term Investment Analysis - Stock Traders Daily
INmune Bio stock dips on $13M securities offering - MSN
Inhibrx Biosciences director buys shares worth nearly $100k - Investing.com
Inhibrx Biosciences director buys shares worth nearly $100k By Investing.com - Investing.com Canada
Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX) By GuruFocus - Investing.com Canada
Inhibrx Biosciences director buys shares worth nearly $100k By Investing.com - Investing.com UK
Inhibrx director Kristiina Vuori buys $99,960 in company stock By Investing.com - Investing.com Australia
Inhibrx CEO Mark Lappe buys $596,762 worth of company stock - Investing.com
Inhibrx director Kristiina Vuori buys $99,960 in company stock - Investing.com
Inhibrx CEO Mark Lappe buys $596,762 worth of company stock - Investing.com India
Inhibrx CEO Mark Lappe buys $596,762 worth of company stock By Investing.com - Investing.com Canada
Inhibrx director Kristiina Vuori buys $99,960 in company stock - Investing.com India
Inhibrx director Kristiina Vuori buys $99,960 in company stock By Investing.com - Investing.com Canada
Around $2M Bet On Franklin Resources? Check Out These 4 Stocks Executives Are Buying - Benzinga
Inhibrx biosciences director Kimberly Manhard buys $139,800 in stock - Investing.com India
Inhibrx biosciences director Kimberly Manhard buys $139,800 in stock - Investing.com
Inhibrx biosciences director Kimberly Manhard buys $139,800 in stock By Investing.com - Investing.com South Africa
Where are the Opportunities in (INBX) - Stock Traders Daily
Inhibrx gains after insider purchases from CEO - MSN
Hedge Fund and Insider Trading News: Boaz Weinstein, Bill Ackman, Third Point, AQR Capital Management, Inhibrx Biosciences Inc (INBX), Comstock Resources Inc (CRK), and More - Insider Monkey
Inhibrx stock gains after CEO insider purchase (NASDAQ:INBX-DEFUNCT-599450) - Seeking Alpha
INBX Stock Earnings: Inhibrx Biosciences Beats EPS for Q2 2024 - MSN
Home Genius Exteriors® skyrockets into top 35 companies In Qualified Remodeler TOP 500 for 2024 - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCRB, PALT, MRO on Behalf of Shareholders - The Malaysian Reserve
Specialty Chemicals Market size is set to grow by USD 368.2 billion from 2024-2028, Increasing demand for specialty chemicals from agrochemical industry boost the market, Technavio - The Malaysian Reserve
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - Financial Times
FINBOA Ranks #650 on Inc. 5000 Fastest Growing Companies List - The Malaysian Reserve
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - PR Newswire
Inhibrx Biosciences Inc.’s latest rating changes from various analysts - Knox Daily
(INBX) Investment Report - Stock Traders Daily
Inhibrx stock rated 'Market Perform' by JMP after Sanofi acquisition - Investing.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):